The Evaluation To The Near Efficacy Of Regimen FOLFOX6 And DOF In The Treatment Of Advanced Gastric Cancer

Objective To evaluate the efficacy and safety of FOLFOX6 combined with DOF neoadjuvant chemotherapy for advanced gastric cancer (Stage T3~4N0~3M0). Methods Retrospective analysis the clinical data of 64 cases with advanced gastric cancer form the gastrointestinal surgery department in the affiliated hospital of qinghai university. 36 patients were accepted FOLFOX6 scheme (Group A): 85mg/m2 Oxaliplatin (L-OHP), ivgtt, 2h, 1st day; 400mg/ m2 Calcium Leucovorin (LV) ivgtt, 2h, 1st day; 200mg/ m2 Fluorouracil (5-FU), iv, 1st day; 2400mg/ m2 fluorouracil (5-FU), continuous intravenous pumping, 44~46h; 28 patients were accepted DOF (group B): 60mg/m2 Docetaxelnto(TXT), ivgtt, 2h, 1st day; 85mg/m2 Oxaliplatin (L-OHP), ivgtt, 2h, 1st day; 400mg/ m2 Calcium Leucovorin (LV) ivgtt, 2h, 1st day; 200mg/ m2 Fluorouracil (5-FU), iv, 1st day; 2400mg/ m2 fluorouracil (5-FU), continuous intravenous pumping, 44~46h. The cycle was 14 day. Evaluated the clinical curative effect after 2~3 cycles for two groups. If had surgery opportunity then rested 21~28 day before surgery. Result Group A: CR 1 case, PR 13 cases, SD 19 cases, PD 3 cases, the clinical control and the total effective rate were 91.7%,38.9%; Group B: CR 1 case, PR 13 cases, SD 12 cases, PD 2 case, the clinical control and the total effective rate were 92.9%,50.0%; The neoadjuvant chemotherapy curative effect of two groups were significant difference (P<0.05). The R0 resection rate of group A (55.6%) was lower than group B (85.7%) (P<0.05), The postoperative complications rate (in 3 months) of group A compared group B (19.4%: 17.9%) was no significant difference (P>0.05); The main adverse reactions of the two groups were granulocytopenia, gastrointestinal adverse reactions, peripheral nerve toxicity, et al. The adverse reaction of group A compared group B was no significant difference (P>0.05). The two groups of patients who were followed up for 6 months were not dead. Conclusion The curative effect for dvanced gastric cancer of group A (Oxaliplatin, Calcium Leucovorin, Fluorouracil) and group B (Docetaxe, Oxaliplatin, Calcium Leucovorin, Fluorouracil) were exact, and the adverse reactions were acceptable. Thecurative effect and R0 resection rate of neoadjuant chemotherapy were superior than the former.